Medicine for diagnosing lung cancer through < 19 > F MRI and application thereof
The 19F MRI nanocontrast agent that uses DMXAA to activate coagulation response and CREKA modified 19F MRI nanocontrast agent was solved through the two-component nanoplatform, and the low sensitivity of 19F MRI in the diagnosis of metastatic tumors of lung cancer was achieved, achieving accurate detection and targeting of early lung metastatic cancer. Treatment, filling the test gap and promoting the clinical application of 19F MRI.
Patent Information
- Application Number
- CN202410984071.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
AI Technical Summary
19F MRI faces safety problems caused by the development of ultra-high field magnetic field equipment with low sensitivity and high cost when diagnosing metastatic tumors of lung cancer. The accumulation of traditional targeted nanocontrast agents at target sites is limited, making it difficult to achieve early detection.
The two-component nanoplatform was adopted to recruit fibrin through DMXAA activation of the coagulation reaction, and target fibrin using CREKA-modified 19F MRI nanocontrast agent to achieve early diagnosis and targeted treatment of lung cancer.
It realizes accurate judgment of micro metastatic lesions and early tumor diagnosis, fills the gap in early lung metastatic cancer detection by 19F MRI, without the need to improve existing magnetic resonance equipment, is highly operable and has clinical promotion value.
Smart Images

Figure HDA0004956892940000011 
Figure HDA0004956892940000012 
Figure HDA0004956892940000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nuclear magnetic resonance imaging, and specifically relates to a method for 19 Drugs and their applications in the diagnosis of lung cancer using F MRI. Background Art
[0002] The metastasis rate of breast cancer is high, and one-third of breast cancer patients will eventually develop metastasis in distant organs, increasing the risk of death. Early and accurate detection and differential diagnosis of breast cancer with micrometastatic lesions will help design more effective patient-specific therapies. Unlike primary tumors, metastatic tumors are characterized by small size, high diversity, and distribution in different organ environments, which poses a major challenge to diagnosis and treatment. For lung metastases caused by breast cancer metastases to the lungs, only one in five patients with lung metastases can survive for more than five years. A large amount of clinical literature emphasizes the importance of early detection of metastases in preventing their further development and potential cure. Therefore, when metastases exist in the form of small but highly disseminated clusters of malignant cells, we need to develop new means to accurately screen metastases.
[0003] MRI is an important means of cancer diagnosis because it has many advantages over other detection technologies, including no radiation, no penetration limitation, excellent spatial resolution, and non-invasiveness for real-time monitoring. 1 H MRI supplement, 19 FMRI has a relatively high sensitivity (83% 1 H) and 100% natural abundance, as well as a wide range of chemical shifts (>350ppm) and very low endogenous background interference in vivo ( 19 F MRI mainly exists in solid form in bones and teeth, and its T2 is extremely short, which makes it impossible to acquire it with existing magnetic resonance equipment. 19 F MRI).
[0004] Although great progress has been made in clinical research over the past few decades, 19 The application of F MRI in the diagnosis of patient diseases is still subject to several challenges, which seriously hinders 19 The most difficult and decisive challenge among these challenges is its inherent low sensitivity. From an instrumentation perspective, the development of ultra-high field MRI instruments may improve 19 F MRI has the potential to improve performance, but it also raises safety and cost issues. In addition, the possibility of further increasing the magnetic field strength is very limited. Another promising approach to overcome this limitation is to use high-performance 19 F MRI probe. Ideal 19 F MRI probes should contain high concentrations of chemically equivalent fluorine nuclei to produce clear and intense 19 F MR signal.
[0005] Perfluoro-15-crown-5-ether (PFCE) is a macrocyclic compound with 20 equivalent fluorine atoms, eliminating the risk of chemical shift artifacts. Magnetic resonance equipment has a clear recognition of the PFCE fluorine signal, maximizing the SNR and providing a single sharp characteristic peak. PFCE is used as a target for cell tracking and targeted drug delivery purposes. 19 F MRI nanocontrast agents have been extensively studied. Formulating PFCE into oil-in-water (o / w) nanoemulsions is the most common strategy to overcome its poor water solubility. Although PFCE nanoparticles (PFCE NPs) can be targetedly modified to increase tumor uptake and have a high density of fluorine atoms to achieve high target / non-target contrast and quantitative primary tumor 19 Although F MR imaging is currently available, detecting metastatic tumors remains challenging. This difficulty is due to the lack of biomarkers for active targeting and the weakening of the enhanced permeability and retention (EPR) effect, which limits the passive accumulation of PFCE at target sites. Summary of the invention
[0006] In order to solve the above problems in the prior art, the present invention provides a 19 F MRI diagnosis of lung cancer drugs and their applications, the present invention constructs a two-component nano-platform by amplifying the targeted 19 F MRI detects lung cancer, such as lung metastasis. The present invention first uses DMXAA (a vascular system disruptor) to precisely activate coagulation in lung metastasis lesions, and then uses communication to recruit fibrin to recruit targeted fibrin. 19 F MRI probe (Flip-CREKA NPs). Compared with the traditional targeting strategy, the targeting strategy of the present invention can be 19 F MRI is used to determine whether a patient has lung cancer. 19 FMRI can be used to diagnose early tumor metastasis, and this approach can even be extended to metastasis-targeted therapy in various tissues, with the potential to combat these threatening diseases.
[0007] The technical solution adopted to achieve the above-mentioned purpose of the present invention is:
[0008] A kind of 19 Drugs for the diagnosis of lung cancer by F MRI include vascular disruptors that can induce coagulation cascade reactions in lung cancer tissues of lung cancer models and fibrinogens that can target 19 F MRI nanocontrast agent.
[0009] Furthermore, the vascular damaging agent is DMXAA.
[0010] Further, the 19F MRI nanocontrast agent is a core-shell structure, 19 The F MRI nanocontrast agent has perfluoro-15-crown-5-ether as the core and liposome as the shell, and the shell is modified with a CREKA short peptide.
[0011] The amino acid sequence of CREKA is Cys-Arg-Glu-Lys-Ala (cysteine-arginine-glutamic acid-lysine-alanine), which is a peptide sequence that can target fibrin. (Li S, Zhang Y, Ho SH, Li B, Wang M, Deng X, Yang N, Liu G, Lu Z, Xu J, Shi Q, Han JY, Zhang L, Wu Y, Zhao Y, Nie G. Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. Nat Biomed Eng. 2020 Jul; 4(7): 732-742. doi: 10.1038 / s41551-020-0573-2. Epub 2020 Jun 22. PMID: 32572197.)
[0012] Furthermore, the liposome is prepared from distearoylphosphatidylcholine, cholesterol and phospholipid polyethylene glycol maleimide as raw materials, and the mass ratio of distearoylphosphatidylcholine, cholesterol and phospholipid polyethylene glycol maleimide is 13:5:2.
[0013] A drug is prepared by 19 F MRI in the diagnosis of lung cancer.
[0014] The drug is 19 F MRI is used to diagnose lung metastases as follows:
[0015] S1. The vascular disruptor DMXAA is injected into the lung cancer model by intravenous injection. The vascular disruptor DMXAA can specifically and efficiently target the lung tumor area of the lung cancer model. The vascular disruptor DMXAA induces bleeding in the lung tumor area of the tumor model and activates the coagulation cascade reaction, thereby aggregating fibrin to the lung tumor area of the lung cancer model.
[0016] S2. Inject targeted fibrin into lung cancer models by intravenous injection. 19Flip-CREKA, a nano-contrast agent for MRI, achieves specific binding of the target head CREKA to the target fibrin. 19 The F MRI nanocontrast agent Flip-CREKA accumulates in the lung metastatic tumor area, thereby 19 F MRI is a non-invasive method to determine whether a person has lung cancer.
[0017] Furthermore, the lung cancer is lung metastasis cancer.
[0018] Compared with the prior art, the advantages and beneficial effects of the present invention are:
[0019] 1. The present invention uses a two-component nano-platform as a new type of 19 F MRI is a drug for diagnosing lung metastatic cancer and can detect tiny metastatic lesions.
[0020] 2. This invention is first passed 19 F MRI is used to diagnose early-stage tumors (such as lung metastasis), filling the gap between 19 F MRI cannot detect early-stage tumors such as lung metastases.
[0021] 3. The method of the present invention uses a two-component nano-platform to diagnose early tumors. There is no need to improve the existing magnetic resonance equipment. The sequences are all sequences that come with the instrument, which has strong operability and is expected to be promoted and applied in clinical practice.
[0022] 4. The present invention uses two-component nanomedicine 19 F MRI can be used to non-invasively determine whether a patient has lung cancer (such as lung metastasis). BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Prepared in Example 1 19 F Cryo-electron microscopy image of MRI nanocontrast agent.
[0024] Figure 2 In vivo fluorescence image of the lung metastasis cancer model mouse constructed in Experiment 1.
[0025] Figure 3 Prepared in Example 1 19 F MRI nanocontrast agent at different concentrations 19 F MRI image.
[0026] Figure 4 CD31 / Fibrin fluorescence staining of lung tumor sections in a lung metastasis cancer model injected with the vascular disruptor DMXAA and saline
[0027] Figure 5 The mouse model of lung metastasis cancer was treated with two-component drugs in vivo1 H MRI, 19 F MRI image. DETAILED DESCRIPTION
[0028] In order to facilitate those skilled in the art to understand and implement the present invention, the present invention is further described in detail below in conjunction with embodiments. It should be understood that the implementation examples described herein are only used to illustrate and explain the present invention and are not used to limit the present invention.
[0029] Example 1
[0030] 1. Take a 25mL round-bottom flask, weigh 65mg DSPC, 25mg cholesterol and 10mg DSPE-PEG2000-MAL and put them into the round-bottom flask, then add 5mL trifluoromethane, stir to dissolve, and after complete dissolution, spin dry at 55℃ to form a film.
[0031] 2. Add 6 mL of ultrapure water and 0.1 μL of perfluoro-15-crown-5-ether (PFCE) to the round-bottom flask containing the membrane obtained in step 1, and ultrasonicate for 30 min in an ice bath (ultrasonic power 130 W) to obtain nanoparticles PFCE@Liposome, abbreviated as Flip.
[0032] 3. Add 20 mg of CREKA short peptide to the obtained nanoparticle Flip and react on a shaker at 37°C and 200 rpm for 12 h to obtain 19 F MRI nanocontrast agent PFCE@Liposome-CREKA, abbreviated as Flip-CREKA.
[0033] The prepared 19 F MRI nanocontrast agent Flip-CREKA was photographed using a cryo-electron microscope. The cryo-electron microscope image is shown below. Figure 1 As shown by Figure 1 It can be seen that 19 The structure of F MRI nanocontrast agent is a core-shell spherical structure, and the liposome shell wraps the liquid fluoride PFCE.
[0034] 19 CREKA modified on the surface of F nanocontrast agent can target the increased fibrin in the lung metastasis tumor area caused by DMXAA drug. Flip-CREKA is highly enriched in the lung tumor area, and combined with its own high-isotope fluorine properties, it can illuminate the lung tumor area. We can judge whether there is lung metastasis cancer from the bright spot signal in the lung.
[0035] Experiment 1: Construction of lung metastasis cancer model
[0036] Experimental methods:
[0037] Culture 4T1-luc cells (mouse breast cancer cells-LUC), digest the 4T1-luc cells in the logarithmic growth phase with trypsin, and disperse them in sterile PBS. The concentration of 4T1-luc cells was controlled to be about 5×10 6 / mL, and obtain a cell suspension. Inject 200uL of the cell suspension into BALB / c mice by intravenous injection. On the 7th day of growth, inject D-luciferin (10μL / g) into BALB / c mice by intravenous injection during the window period, and then verify whether the model is successful by in vivo fluorescence.
[0038] Experimental results:
[0039] In vivo fluorescence images of BALB / c mice Figure 2 As shown, from Figure 2 As can be seen in the figure, BALB / C mice have 4T1-luc bioluminescence in their lungs, indicating the occurrence of lung cancer, indicating that the model was successful. BALB / c mice with successful lung metastasis on day 7 can be used for DMXAA drug performance verification and in vivo 19 F MRI imaging experiment. Experiment 2: The present invention 19 In vitro F MRI nanocontrast agents 19 F MRI experiments
[0040] Experimental methods:
[0041] 1. Prepared in Example 1 19 F MRI nanocontrast agent (fluorine atomic concentration of 2000 mM) was diluted with ultrapure water to prepare Flip-CREKA solutions with fluorine atomic concentrations of 2000, 1500, 1000, 750, 500, and 250 mM, respectively.
[0042] 2. Take 0.5 mL of each concentration of Flip-CREKA solution and transfer it to a 5 mm NMR sample tube. Fix it into a circle according to the concentration from low to high, and tune and homogenize it in a 400M magnetic resonance imaging spectrometer. 19 In the F MRI imaging experiment, the RARE sequence was used for data acquisition, with 64 repeated samplings, a sampling matrix of 32×32, a scanning time of 409 s, and the other sampling parameters were set as follows: acceleration factor RARE factor = 4, repetition time TR = 800.0 ms, and echo time TE = 3 ms.
[0043] Experimental results:
[0044] Different concentrations of Flip-CREKA solution 19 F MRI images Figure 3 As shown by Figure 3It can be seen that Flip-CREKA solutions of different concentrations have good imaging performance, providing reliable support for subsequent in vivo lung imaging.
[0045] Experiment 2: Verifying the ability of the drug DMXAA to induce an increase in tumor fibrin
[0046] Experimental methods:
[0047] 1. DMXAA was dispersed in physiological saline and injected into the lung metastasis cancer model constructed in Experiment 1 through the tail vein (100 μL / each). The mice were raised normally and the tumor tissue was removed by dissection after 12 hours. After fixation with paraformaldehyde, it was embedded in paraffin to obtain experimental tumor tissue sections.
[0048] 2. Physiological saline was injected into the lung metastasis cancer model constructed in Experiment 1 through the tail vein (100 μL / each mouse). The mice were raised normally and the tumor tissues were removed by dissection 12 hours later. After polymethyl methacrylate fixation, the tissues were embedded in paraffin to obtain control tumor tissue sections.
[0049] 3. Perform CD31 / Fibrin fluorescent double-labeling staining on the experimental tumor tissue sections and the control tumor tissue sections respectively.
[0050] Experimental results:
[0051] CD31 / Fibrin fluorescence staining of experimental tumor tissue sections and control tumor tissue sections are shown in Figure 4 As shown, CD31 / Fibrin fluorescence staining ( Figure 4 ) confirmed that the new blood vessels indicated by CD31 in the lung tumor area of the lung metastasis cancer model treated with DMXAA were significantly reduced, and obvious fibrin green fluorescence was shown, indicating that the fibrin in the lung tumor area of the lung metastasis cancer model was significantly increased. However, no obvious fibrin green fluorescence was observed in the lung tumor area of the lung metastasis cancer model treated with normal saline. In addition, the fibrin content of normal lung tissue around the lung tumor in the lung metastasis cancer model was low, indicating that the first step of the strategy of increasing fibrin by DMXAA drugs is effective and feasible.
[0052] Experiment 3: Experiment on diagnosis of lung metastasis by using the dual-component drug of the present invention
[0053] Experimental methods
[0054] 1. DMXAA was dispersed in physiological saline to obtain DMXAA solution, which was then injected into the lung metastasis cancer model constructed in Experiment 1 through the tail vein (0.3 mg DMXAA / each).
[0055] 2. 12 hours after the injection of DMXAA solution, the lung metastasis cancer model was injected with the prepared in Example 1 via tail vein injection. 19F MRI nanocontrast agent Flip-CREKA (injection amount with fluorine concentration of 80 mmol).
[0056] 3. Use first 1 T2WI in HMRI localizes the lung tumor area in the lung metastasis cancer model. 1 HMRI used the RARE imaging sequence, with a TR of 2500 ms, a TE of 11 ms, a FOV of 2.5 × 2.5 cm, a slice thickness of 1.5 mm, a matrix size of 256 × 256, an acceleration factor of 8, 16 samplings, and a sampling time of 16 min. 19 F MRI localizes the lung tumor area in the lung metastasis cancer model. 19 F MRI selected the RARE imaging sequence, with a TR of 2500 ms, a TE of 3 ms, a FOV of 3.09 × 3.09 cm, a slice thickness of 16.17 mm, a matrix size of 32 × 32, an acceleration factor of 4, and 160 sampling times.
[0057] Experimental results:
[0058] Lung metastasis model lung tumors were treated with DMXAA and 19 F MRI nanocontrast agent treated in vivo 1 H MRI images, 19 FMRI images are Figure 5 As shown, through the living 1 H T2-weighted-MRI images can show the lung tumor area of the lung metastasis model. Although current clinical MRI examinations are mainly based on proton ( 1 H) imaging, but there is a disadvantage of interference from tissue background signals, as we have seen 1 H images are difficult to identify tiny lesions. 19 F MRI shows that the lung metastasis model has bright spot signals in the lung, which has a higher contrast with normal tissue and can overcome 1 The low sensitivity and background signal interference of H MRI are of great significance for the early and accurate detection of lung cancer. The H&E staining image also shows that there are tumor areas in the lungs of this lung metastasis cancer model. 19 F MRI images confirmed the presence of cancer lesions in the lungs, which was consistent with the H&E staining images (corresponding to clinical biopsy - the gold standard).
[0059] In the lung metastatic cancer model, DMXAA induces a coagulation cascade reaction in the lung tumor area, triggering fibrin aggregation. 19 F MRI nanocontrast agent specific binding, to achieve 19F MRI nanocontrast agents accumulate in the lung metastasis area, thereby improving the location of lung metastasis lesions 19 The signal-to-noise ratio (SNR) of F MRI has been greatly improved. 19 F MRI accuracy and precision in detecting lung metastatic tumor lesions.
[0060] In summary, the two-component drug of the present invention can diagnose whether a patient has lung metastatic cancer with high accuracy and precision, and does not require invasive means such as biopsy.
Claims
1. A method of 19 F MRI diagnosis of lung cancer drugs, characterized by: These include vascular disruptors that can induce a coagulation cascade in lung cancer tissue of a lung cancer model and fibrinogens that can target 19 F MRI nanocontrast agent.
2. The method according to claim 1 19 F MRI diagnosis of lung metastatic cancer drugs, characterized by: The vascular damaging agent is DMXAA.
3. The method according to claim 1 19 F MRI diagnosis of lung cancer drugs, characterized by: The 19 F MRI nanocontrast agent is a core-shell structure. 19 The F MRI nanocontrast agent has perfluoro-15-crown-5-ether as the core and liposome as the shell, and the shell is modified with a CREKA short peptide that can target fibrin.
4. The method according to claim 3 19 F MRI diagnosis of lung cancer drugs, characterized by: The liposome is prepared from distearoylphosphatidylcholine, cholesterol and phospholipid polyethylene glycol maleimide as raw materials, and the mass ratio of distearoylphosphatidylcholine, cholesterol and phospholipid polyethylene glycol maleimide is 13:5:
2.
5. A drug according to claim 1, in the preparation of 19 F MRI in the diagnosis of lung cancer.
6. The use of the drug according to claim 1, characterized in that: The lung cancer is lung metastatic cancer.
Citation Information
Patent Citations
EGFR-targeting perfluorocarbon nanoprobe 19F magnetic resonance imaging as well as preparation method and application
CN110393810A
Diagnosis-treatment Integrated nano-probe for 19F-MR / fluorescence multi-mode molecular imaging and drug-loading and preparation method and application of nano-probe
CN110433296A
Detecting and treating solid tumors through selective disruption of tumor vasculature
US20130323167A1
